Prabotulinumtoxin a
Prabotulinumtoxin a is an unknown pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Jeuveau
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| jeuveau | Biologic Licensing Application | 2023-04-28 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
85 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Migraine disorders | D008881 | EFO_0003821 | G43 | 1 | 3 | 1 | 2 | — | 6 |
| Stroke | D020521 | EFO_0000712 | I63.9 | 1 | 1 | 1 | 1 | 1 | 4 |
| Cicatrix | D002921 | — | L90.5 | — | 1 | 1 | 1 | — | 2 |
| Aging | D000375 | GO_0007568 | R41.81 | — | — | — | 1 | — | 1 |
| Fissure in ano | D005401 | — | K60.2 | — | — | — | 1 | — | 1 |
| Headache | D006261 | — | R51 | — | — | — | 1 | — | 1 |
| Skin neoplasms | D012878 | EFO_0004198 | C44 | — | — | — | 1 | — | 1 |
| Graves ophthalmopathy | D049970 | EFO_1001466 | — | — | — | — | 1 | — | 1 |
| Rejuvenation | D012060 | — | — | — | — | — | 1 | — | 1 |
| Facies | D019066 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Muscle spasticity | D009128 | — | — | 1 | 1 | 2 | — | 4 | 7 |
| Urinary incontinence | D014549 | — | R32 | — | — | 4 | — | 1 | 5 |
| Overactive urinary bladder | D053201 | EFO_1000781 | N32.81 | — | — | 3 | — | 1 | 4 |
| Cerebral palsy | D002547 | — | G80 | — | 1 | 1 | — | — | 2 |
| Hypertrophic cicatrix | D017439 | — | L91.0 | — | 1 | 1 | — | — | 1 |
| Hypertrophy | D006984 | EFO_0002460 | — | — | — | 1 | — | — | 1 |
| Urinary bladder diseases | D001745 | — | N32.9 | — | — | 1 | — | — | 1 |
| Spinal cord injuries | D013119 | EFO_1001919 | — | — | — | 1 | — | — | 1 |
| Hereditary sensory and autonomic neuropathies | D009477 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Torticollis | D014103 | — | F45.8 | 1 | 3 | — | — | 1 | 4 |
| Dystonic disorders | D020821 | — | G24 | 1 | 2 | — | — | 1 | 3 |
| Dystonia | D004421 | — | — | 1 | 2 | — | — | — | 2 |
| Depression | D003863 | — | F33.9 | — | 2 | — | — | — | 2 |
| Hallux valgus | D006215 | — | — | — | 1 | — | — | — | 1 |
| Paresis | D010291 | — | — | — | 1 | — | — | — | 1 |
| Paraplegia | D010264 | — | G82.2 | — | 1 | — | — | — | 1 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 1 | — | — | — | 1 |
| Neck pain | D019547 | — | M54.2 | 1 | 1 | — | — | — | 1 |
| Muscle hypertonia | D009122 | — | — | 1 | 1 | — | — | — | 1 |
Show 1 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Complex regional pain syndromes | D020918 | EFO_1001998 | — | 1 | — | — | — | 1 | 2 |
| Blepharospasm | D001764 | — | G24.5 | 1 | — | — | — | — | 1 |
| Skin aging | D015595 | EFO_0005422 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemiplegia | D006429 | — | G81.0 | — | — | — | — | 2 | 2 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 2 | 2 |
| Abdominal hernia | D046449 | — | K46 | — | — | — | — | 1 | 1 |
| Ventral hernia | D006555 | EFO_1001866 | K43 | — | — | — | — | 1 | 1 |
| Internal hernia | D000082122 | — | — | — | — | — | — | 1 | 1 |
| Rosacea | D012393 | — | L71 | — | — | — | — | 1 | 1 |
| Flushing | D005483 | — | R23.2 | — | — | — | — | 1 | 1 |
| Erythema | D004890 | — | L53.9 | — | — | — | — | 1 | 1 |
| Vaginismus | D052065 | — | N94.2 | — | — | — | — | 1 | 1 |
| Sexuality | D019529 | — | — | — | — | — | — | 1 | 1 |
Show 4 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Prabotulinumtoxin a |
| INN | _ |
| Description | Botulinum toxin, or botulinum neurotoxin, is a neurotoxic protein produced by the bacterium Clostridium botulinum and related species. It prevents the release of the neurotransmitter acetylcholine from axon endings at the neuromuscular junction, thus causing flaccid paralysis. The toxin causes the disease botulism. The toxin is also used commercially for medical and cosmetic purposes.
|
| Classification | Neurotoxin |
| Drug class | fluoroquinolone derivatives, nonantibacterial indication (e.g., antineoplastic antibiotics) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297229 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00083 |
| UNII ID | 0A6JH35GMQ (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 124 documents
View more details
Safety
Black-box Warning
Black-box warning for: Jeuveau
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,244 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use